One-year outcomes of pulmonary vein isolation with a novel cryoballoon: Primary results of the FROZEN AF trial.
atrial arrhythmias
atrial fibrillation
cryoballoon ablation
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
revised:
27
01
2024
received:
09
01
2024
accepted:
05
02
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
Cryoablation therapy for pulmonary vein isolation (PVI) to treat paroxysmal atrial fibrillation (PAF) is well established. A novel 28 mm cryoballoon system designed to operate under low pressure to safely reach a lower nadir temperature and maintain constant balloon size during cooling has not been prospectively studied in a large patient population for safety and efficacy. The FROZEN AF (NCT04133168) trial was an international multicenter, open-label, prospective, single-arm study on the safety and performance of a novel cryoballoon system for treatment of PAF. The study enrolled patients at 44 sites in 10 countries across North America, Europe, and Asia. Subjects were indicated for PVI treatment of PAF and had failed or were intolerant of one or more antiarrhythmic drugs. Procedural outcomes were defined based on the 2017 HRS consensus statement. Follow-up was performed at 7 days, 3, 6, and 12 months. Data are reported as mean ± SD or median (IQR). PVI was performed with a 28 mm cryoballoon in 325 drug refractory PAF patients. Complete PVI was achieved in 95.7% of patients. In cryoablation lesions longer than 60 s, 60.1% of PV isolations required only a single cryoballoon application. Procedure related complications included: phrenic nerve palsy [temporary 4 (1.2%), persistent 0 (0.0%)], cardiac tamponade/perforation 2 (0.6%), and air embolism 1 (0.3%). Freedom from documented atrial arrhythmia recurrence at 12 months was 79.9% (AF 82.7%, AFL 96.5%, AT 98.1%), antiarrhythmic drugs (AAD) were continued or re-initiated in 26.8% of patients after the 3-month blanking period. Additionally, an extension arm enrolled 50 pts for treatment with 28/31 mm variable size cryoballoon. A single temporary PNP occurred in this group, which resolved before discharge. Freedom from documented recurrence at 12 months in these pts was 82.0%. This novel cryoballoon may facilitate PVI to treat PAF, providing more options to address the variety of anatomies present in patients with PAF. This cryoballoon system proved to be safe and effective for treatment of patients with drug refractory or drug intolerant PAF.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Boston Scientific Corporation
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498. doi:10.1093/eurheartj/ehaa612
Neumann T, Vogt J, Schumacher B, et al. Circumferential pulmonary vein isolation with the cryoballoon technique. JACC. 2008;52:273-278. doi:10.1016/j.jacc.2008.04.021
Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation. JACC. 2013;61:1713-1723. doi:10.1016/j.jacc.2012.11.064
Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374:2235-2245. doi:10.1056/NEJMoa1602014
Heeger CH, Sohns C, Pott A, et al. Phrenic nerve injury during cryoballoon-based pulmonary vein isolation: results of the worldwide YETI registry. Circ: Arrhythmia Electrophysiol. 2022;15:e010516. doi:10.1161/CIRCEP.121.010516
Tsiachris D, Antoniou CK, Doundoulakis I, et al. Best practice guide for cryoballoon ablation in atrial fibrillation: the compilation experience of more than 1000 procedures. J Cardiovasc Dev Dis. 2023;10(2):55. doi:10.3390/jcdd10020055
Tokuda M, Yamashita S, Shiomi S, et al. Pulmonary vein stenosis after catheter ablation of atrial fibrillation using a cryoballoon, hot balloon, or laser balloon. Circ J. 2023;87:1711-1719. doi:10.1253/circj.CJ-23-0048
Su W, Aryana A, Passman R, et al. Cryoballoon best practices II: practical guide to procedural monitoring and dosing during atrial fibrillation ablation from the perspective of experienced users. Heart Rhythm. 2018;15:1348-1355. doi:10.1016/j.hrthm.2018.04.021
Su W, Kowal R, Kowalski M, et al. Best practice guide for cryoballoon ablation in atrial fibrillation: the compilation experience of more than 3000 procedures. Heart Rhythm. 2015;12:1658-1666. doi:10.1016/j.hrthm.2015.03.021
Chen S, Schmidt B, Bordignon S, et al. Practical techniques in cryoballoon ablation: how to isolate inferior pulmonary veins. Arrhythm Electrophysiol Rev. 2018;7:11-17. doi:10.15420/aer.2018;1;2
Anic A, Lever N, Martin A, et al. Acute safety, efficacy, and advantages of a novel cryoballoon ablation system for pulmonary vein isolation in patients with paroxysmal atrial fibrillation: initial clinical experience. EP Europace. 2021;23:1237-1243. doi:10.1093/europace/euab018
Isonaga Y, Miyazaki S, Nitta J, et al. Acute procedural efficacy and safety of a novel expandable diameter cryoballoon in atrial fibrillation ablation: early results from a multicenter ablation registry. J Cardiovasc Electrophysiol. 2024;35(1):198-205. doi:10.1111/jce.16135
Honarbakhsh S, Martin CA, Mesquita J, et al. Atrial fibrillation cryoablation is an effective day case treatment: the UK PolarX vs. Arctic front advance experience. Europace. 2023;25(11):euad286. doi:10.1093/europace/euad286
Martin CA, Tilz RRR, Anic A, et al. Acute procedural efficacy and safety of a novel cryoballoon for the treatment of paroxysmal atrial fibrillation: results from the POLAR ICE study. J Cardiovasc Electrophysiol. 2023;34:833-840. doi:10.1111/jce.15861
Mojica J, Lipartiti F, Al Housari M, et al. Procedural safety and efficacy for pulmonary vein isolation with the novel polarx cryoablation system: a propensity score matched comparison with the arctic front cryoballoon in the setting of paroxysmal atrial fibrillation. J Atr Fibrillation. 2021;14:20200455. doi:10.4022/jafib.20200455
Assaf A, Bhagwandien RE, Szili-Torok T, Yap SC. Comparison of the acute outcome of two cryoballoon technologies for pulmonary vein isolation: an updated systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2022;42:101115. doi:10.1016/j.ijcha.2022.101115
Bianchi S, De Simone A, Iacopino S, et al. Pulmonary vein isolation by means of a novel cryoballoon technology in paroxysmal atrial fibrillation patients: 1-year outcome from a large Italian multicenter clinical registry. Pacing Clin Electrophysiol. 2023;46:1302-1309. doi:10.1111/pace.14839
Guckel D, Lucas P, Isgandarova K, et al. Impact of pulmonary vein variant anatomy and cross-sectional orifice area on freedom from atrial fibrillation recurrence after cryothermal single-shot guided pulmonary vein isolation. J Interv Card Electrophysiol. 2022;65:251-260. doi:10.1007/s10840-022-01279-w
Heeger CH, Popescu SS, Inderhees T, et al. Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study. Europace. 2023;25(9):euad248. doi:10.1093/europace/euad248
Martin A, Fowler M, Breskovic T, et al. Novel cryoballoon to isolate pulmonary veins in patients with paroxysmal atrial fibrillation: long-term outcomes in a multicentre clinical study. J Interv Card Electrophysiol. 2022;65:609-616. doi:10.1007/s10840-022-01200-5
Heeger CH, Pott A, Sohns C, et al. Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study. EP Europace. 2022;24:1917-1925. doi:10.1093/europace/euac148
Ayoub T, El Hajjar AH, Singh Sidhu GD, et al. Esophageal temperature during atrial fibrillation ablation poorly predicts esophageal injury: an observational study. Heart Rhythm O2. 2021;2:570-577. doi:10.1016/j.hroo.2021.11.002
Koranne K, Basu-Ray I, Parikh V, et al. Esophageal temperature monitoring during radiofrequency ablation of atrial fibrillation: a meta-analysis. J Atr Fibrillation. 2016;9:1452. doi:10.4022/jafib.1452
Razzack AA, Lak HM, Pothuru S, et al. Efficacy and safety of catheter ablation vs antiarrhythmic drugs as initial therapy for management of symptomatic paroxysmal atrial fibrillation: a meta-analysis. Rev Cardiovasc Med. 2022;23:112. doi:10.31083/j.rcm2303112
Kuck KH, Fürnkranz A, Chun KRJ, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. Eur Heart J. 2016;37:2858-2865. doi:10.1093/eurheartj/ehw285
Kuniss M, Pavlovic N, Velagic V, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. EP Europace. 2021;23:1033-1041. doi:10.1093/europace/euab029
Knight BP, Novak PG, Sangrigoli R, et al. Long-term outcomes after ablation for paroxysmal atrial fibrillation using the second-generation cryoballoon. JACC Clin Electrophysiol. 2019;5:306-314. doi:10.1016/j.jacep.2018.11.006
Verma A, Haines DE, Boersma LV, et al. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation. 2023;147:1422-1432. doi:10.1161/CIRCULATIONAHA.123.063988
Reddy VY, Gerstenfeld EP, Natale A, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med, 2023;389:1660-1671. doi:10.1056/NEJMoa2307291